The Swedish Knowledge-Foundation has granted SEK 12 million to a project concerning individual immunity profiles for diagnostics and medical development based on Attana's QCM technology.
The Swedish Knowledge-Foundation has granted SEK 12 million to the project "Advanced materials for individualized medicine and diagnostics (https://www.kks.se/article/35-miljoner-till-forskning-i-samproduktion-med-naringslivet/)". The project is coordinated by Prof. Ian Nicholls at Linnaeus University (https://lnu.se/en/research/research-projects/project-advanced-materials-for-personal-medicine-and-diagnostics/) in collaboration with Attana AB, AroCell AB, Capitainer AB, Luma Metall AB and Region Kalmar.
The aim of the project is to provide precise information about the medical conditions of individuals and groups to optimize vaccination and medical treatment. It enables individuals, patients, care providers and decision makers, as well as researchers to optimize their decisions. The project includes the entire chain from sampling, via analysis to reporting. The project's participants gather expertise from the commercial and public sectors as well as researchers and developers.
The project consists of four sub-projects:
1. Biomarkers: Cancer biomarker detection - small cell lung cancer (Project manager: Ian Nicholls).
2. Viruses: Virus-related diseases: e.g. COVID-19 and hepatitis (Project manager: Per Nilsson).
3. Bacteria: Enhanced bacterial infection diagnosis - Lyme disease & E.coli related urinary tract infections (Project manager: Sofia Somajo).
4. Tissue samples: Biosensor-based histology - glaucoma & macular degeneration (Project manager: Camilla Mohlin).
Sub-project 1-3 builds directly on Attana's immunity profile concept and sampling with Capitainer's qDBS concept. Subproject 4 is based on Attana's tissue-based biosensors.
Shortly we will publish PMs regarding each specific sub-project and its importance for Attana.
Attana's CEO Teodor Aastrup comments:
"The project strengthens our capabilities in immunity profiles and ensures the necessary expertise and funding for the further development of immunity profiles. Thereby we can allocate the necessary resources to this project and at the same time focus other resources on our regular commercial activities."